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OBJECTIVE: To describe the length of stay, cost of 
drug treatment, diagnostic tests and other therapeutic
measures in acute psychotic patients admitted to acute 
in-patient psychiatric units and to analyse the factors
associated with these. METHODS: Retrospective review
of medical records of 200 patients admitted for acute 
psychosis in 8 Spanish hospitals. Description of the length
of stay, cost of drug treatment and diagnostic tests; bivari-
ate and multivariate analysis of factors associated with
length of stay and cost of antipsychotic drug treatment.
RESULTS: The average admission cost ranged between
€2,830.29 and €3,624.95, with a wide variability among
hospitals. Of this cost, 94.3% corresponded to ﬁxed
costs, 3.4% to diagnostic tests and 2.4% to drug 
treatment (84.2% of this latter cost corresponded to
antipsychotic drugs). An age younger than 25 years and
a diagnosis of schizophrenia were associated with longer
hospital stays; longer length of stay, the presence of
aggressiveness/agitation, a diagnosis of schizophrenia, age
younger than 25 years and the use of atypical antipsy-
chotics were associated with higher costs in antipsychotic
drug treatment. CONCLUSIONS: The hospital admis-
sion cost of an acute psychotic episode is mostly depen-
dent on the structural costs derived from in-patient
treatment. The differences in costs seem to be related to
different length of stay schemes used by the various hos-
pitals rather than to the clinical characteristics of patients
or the drugs used.
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OBJECTIVES: To compare antipsychotic medication 
patterns, side-effects and concomitant medication usage
for olanzapine and haloperidol patients in a cross-
sectional analysis of the GEO observational study.
METHODS: GEO is a 2-year prospective naturalistic
combined in- and outpatient observational study in
Germany. 646 adult schizophrenia patients treated with
either olanzapine (N = 416) or haloperidol (N = 230)
were enrolled in the study and quarterly observations on
the disease course, resource consumption and quality of
life are made during the follow-up period. RESULTS:
More olanzapine patients were newly switched to their
current treatment (27% vs. 18% within 2 weeks before
enrolment) or switched more than 2 weeks but less than
3 months before enrolment (19% vs. 12%). Patients
switched within the last 3 months had spent more days
in hospital during the last year than patients treated for
more than 3 months (29 days vs. 15 days). In the 12
months prior to being enrolled in the study, olanzapine
patients had spent more days in hospital due to schizo-
phrenia compared with the haloperidol patients (23 vs.
19 days). Olanzapine patients had lower incidence of
treatment related EPS side-effects (27% vs. 70%),
whereas other treatment side-effects (mainly related to
adipositas and depression) were reported more frequently
for olanzapine patients (29% vs. 9%). A smaller 
proportion of olanzapine patients received concomitant
antipsychotic medication (31.0% vs. 48.7%) and EPS
medication (1.6% vs. 20.5%) compared with haloperidol
patients. The concomitant use of antidepressants (24.8%
vs. 5.4%) and anxiolytics (24.0% vs. 13.4%) were more
common for olanzapine compared with haloperidol
patients. CONCLUSIONS: At time of enrolment in the
GEO observational study, more olanzapine patients were
recently switched to their current treatment, and had
spent more days in hospital. Additional antipsychotic
medication use was more common for haloperidol
patients. Olanzapine patients had fewer treatment 
side-effects and lower usage of concomitant side-effects
medication.
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OBJECTIVES: To compare disease characteristics, living
situations and employment status for schizophrenia
patients treated with olanzapine or haloperidol in a 
cross-sectional analysis of the GEO observational study.
METHODS: GEO is a 2-year prospective naturalistic
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combined in- and outpatient observational study in
Germany. 646 adult schizophrenia patients treated with
either olanzapine (N = 416) or haloperidol (N = 230)
were enrolled in the study and quarterly observations on
the disease course, resource consumption and quality of
life are made during the follow-up period. RESULTS: In
both treatment groups nearly 50% of the patients were
female, had been diagnosed around the age of 30 years,
and were overweight (BMI > 25). Hospital inpatients and
hospital day care patients were more severely ill (N = 230,
>50% with CGI clearly ill or worse) than outpatients (N
= 416, >50% with CGI moderate or better). For both
treatment groups the global disease severity was similar
(approximately 70% moderate or worse, 15% severe or
worse) as well as the existence of positive symptoms
(about 64% had current positive symptoms in both
groups). Olanzapine patients were younger (mean 39 vs.
46 years). Current negative symptoms (90% vs. 98%)
and cognitive symptoms (88% vs. 95%) were less
common for olanzapine patients than for haloperidol
patients, whereas depressive symptoms were more
common (75% vs. 69%). More olanzapine patients were
able to care for themselves (87% vs. 78%) and lived at
home without care (57% vs. 40%). More olanzapine
patients were employed (32% vs. 18%) and fewer were
in early retirement (27% vs. 46%). CONCLUSIONS: At
time of enrolment in the GEO observational study 
olanzapine and haloperidol-treated patients had schizo-
phrenia of similar severity but different disease course.
Fewer olanzapine patients had negative or cognitive
symptoms whereas more had depressive symptoms. More
olanzapine patients were employed and able to care for
themselves, whereas more haloperidol patients were in
early retirement.
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OBJECTIVES: To provide a study description and 
baseline socio-demographic, socio-economic and clinical
characteristics of schizophrenia patients treated with
haloperidol, olanzapine or risperidone at time of 
enrolment in the SOS observational study. METHODS:
SOS is a non-randomised 2-year prospective observa-
tional study. Data are collected on treatment costs, 
efﬁcacy, tolerability and patient quality of life using an
internet-based case report form on patients assigned treat-
ment with haloperidol, olanzapine or risperidone during
a recent psychotic episode requiring hospitalisation.
Patients were included within one month from discharge
to part-time hospitalisation or ambulatory care if treat-
ment with the study drug was stable since at least a
month. Data are collected at inclusion and after 3, 6, 12,
18 and 24 months. RESULTS: 323 patients diagnosed
with schizophrenia or schizofreniform disorders (DSM-
IV criteria) have been enrolled in the study. Preliminary
baseline data on 305 patients (males: 65%) show that 32
patients are on haloperidol, 141 on olanzapine and 132
on risperidone. 77% are outpatients. 57% suffer para-
noid schizophrenia. Mean age is 37 ± 13y. The socio-
economic proﬁle (living environment, schooling back-
ground and working activity) is comparable between
treatment groups. “Brief Psychiatric Rating Scale” and
“Clinical Global Impression” scores (overall mean: 32 ±
16 and 4.0 ± 1.2 respectively) are comparable for all
groups. However, some variables such as ﬁrst antipsy-
chotic prescription (haloperidol: 6.3%; olanzapine: 18%;
risperidone: 24%) suggest that there may be differences
between the treatment groups. “Global Assessment of
Functioning” score (mean: 52 ± 14) is signiﬁcantly lower
in the haloperidol group (47 ± 12). General quality of life
(EQ-5D) is comparable for all groups (66 ± 19). “Sub-
jective Well-Being under Neuroleptics” scores are signiﬁ-
cantly worse in the olanzapine group. CONCLUSION:
The SOS observational study will provide substantial
information to increase the understanding of the clinical,
social and economic outcomes and current treatment
modalities in real world clinical practice in the treatment
of schizophrenia in Belgium.
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OBJECTIVE: To compare incidence rates of hyperlipi-
demia among schizophrenia patients treated with 
conventional or newer antipsychotics. METHODS: Inte-
grated claims from a large insured population were used.
Analysis included 614 individuals who: were diagnosed
with schizophrenia (ICD9 295.xx); initiated a typical
antipsychotic, or olanzapine or risperidone; had no use
of any antipsychotics in the prior 6 months. New onset
hyperlipidemia was deﬁned as either two hyperlipidemia
diagnoses (ICD9 272.xx) or prescription for lipid-
lowering agents. One-year incidence rates were compared
using logistic regressions controlling for demographics
and medical comorbidities. Cox proportional hazard
method and Kaplan-Meier survival curves of time-to-
incidence were compared between treatment groups.
RESULTS: Adjusted odds ratios of incidence of hyper-
lipidemia (based on diagnosis and/or treatment) were:
atypical vs. typical 1.684 (p = 0.32); risperidone vs.
typical 1.622 (p = 0.42); olanzapine vs. typical 1.878 
